Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Experiences with Efanesoctocog Alfa: Exit Interviews with Caregivers of Previously Treated Patients with Hemophilia A from the XTEND-Kids Phase 3 Clinical Trial

Lynn Malec, Manuel Carcao, Mary Mathias, Nana Kragh, Jennifer Dumont, Annemieke Willemze, Linda Bystrická, Amanda Wilson, Dana Dibenedetti

Blood (2023) 142 (Supplement 1): 507.

https://doi.org/10.1182/blood-2023-181973

Published: 2023

Journal Articles

Real-World Unmet Needs in Patients with Hemophilia A without Inhibitors in the US: Results from the PicnicHealth Database

Courtney Thornburg, Allison P Wheeler, Sylvie Bozzi, Gandarvaka Miles, Kalyani Hawaldar, Andrew Wilson, Gillian Hanson, Noelle Liao, Amanda Wilson

Blood (2023) 142 (Supplement 1): 2380.

https://doi.org/10.1182/blood-2023-181655

Published: 2023

Journal Articles

Investigating the Relationship between Endogenous Factor VIII Levels and Annual Bleed Rates and Health-Related Quality of Life in Patients with Hemophilia a Not Treated with Factor VIII Prophylaxis

Cheryl Jones, Yunchou Wu, Nana Kragh, Linda Bystrická, Amanda Wilson, Tom Burke

Blood (2023) 142 (Supplement 1): 5125.

https://doi.org/10.1182/blood-2023-180821

Published: 2023

Journal Articles

Experience with Accelerometer Physical Activity Tracking in Adults and Adolescents with Hemophilia A: Tool Validation Using Results from the XTEND-1 Efanesoctocog Alfa Phase 3 Trial

Amanda Wilson, Jérôme Msihid, Nicolai Ayasse, Jennifer Dumont, Annemieke Willemze

Blood (2023) 142 (Supplement 1): 2360.

https://doi.org/10.1182/blood-2023-179751

Published: 2023

Journal Articles

Efficacy of Efanesoctocog Alfa on Pain in Patients with Hemophilia A: Results from the XTEND-1 Phase 3 Clinical Trial in Previously Treated Patients with Hemophilia A

Amanda Wilson, Nana Kragh, Jerome Mshijid, Jennifer Dumont, Annemieke Willemze, Elena Santagostino, Chuanwu Zhang, Roshni Kulkarni, Annette von Drygalski, Pratima Chowdary

Blood (2022) 140 (Supplement 1): 5610–5611.

https://doi.org/10.1182/blood-2022-166849

Published: 2022

Journal Articles

Efficacy of Efanesoctocog Alfa on Physical Functioning: Results from the XTEND-1 Phase 3 Clinical Trial in Previously Treated Patients with Hemophilia A

Amanda Wilson, Nana Kragh, Jennifer Dumont, Jerome Mshijid, Annemieke Willemze, Linda Bystricka, Chuanwu Zhang, Angela C. Weyand, Kathelijn Fischer, Victor Jimenez-Yuste

Blood (2022) 140 (Supplement 1): 5595–5596.

https://doi.org/10.1182/blood-2022-167542

Published: 2022

Journal Articles

A Retrospective Observational Descriptive Study on the Effectiveness and Usage of Emicizumab and Antihemophilic Factor (recombinant), Fc Fusion Protein in Patients with Hemophilia A in the US

Alex Cockerham, Amanda Wilson, Andrew Frick, Pronabesh Dasmahapatra

Blood (2021) 138 (Supplement 1): 3031.

https://doi.org/10.1182/blood-2021-148325

Published: 2021

Journal Articles

Treatment Patterns Among Patients with Immune Thrombocytopenia (ITP) in the United States: An Electronic Medical Record (EMR)-Based Analysis

Amanda Wilson, Ahmed Daak, Jun Su

Blood (2020) 136 (Supplement 1): 43.

https://doi.org/10.1182/blood-2020-140409

Published: 2020

Journal Articles

Longitudinal Analysis of Anemia Severity, Treatment and Healthcare Resource Utilization Among Patients with Primary Cold Agglutinin Disease in a Large US Database

Amanda Wilson, Florence Joly, Gandarvaka Miles, Kammy Kuang, Huy P Pham, MD MPH

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-139637

Published: 2020

Journal Articles

Prophylactic Antibiotic Use and Risk of Meningococcal Infections in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Eculizumab Who Received Meningococcal Vaccination: Results from the International PNH Registry

Christopher J. Patriquin, MDFRCPC,MSc, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Régis Peffault de Latour, MD PhD, Jun-Ho Jang, MD PhD, Saskia Langemeijer, MD PhD, Alexey A. Maschan, MD, Amanda Wilson, PhD, Deepak Jain, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 4802.

https://doi.org/10.1182/blood-2019-127005

Published: 2019

Journal Articles

Efficacy of Eculizumab in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria in the International PNH Registry

Álvaro Urbano-Ispizua, MD PhD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Marije Bartels, MD PhD, Christopher J. Patriquin, MD MSc, FRCPC, Britta Hoechsmann, MD, Alexey A. Maschan, MD, Amanda Wilson, PhD, Philippe Gustovic, MD, Hubert Schrezenmeier, MD

Blood (2018) 132 (Supplement 1): 3614.

https://doi.org/10.1182/blood-2018-99-111306

Published: 2018

Journal Articles

Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry

Regis Peffault De Latour, Jaroslaw P. Maciejewski, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Loree Larratt, MD FRCP(C), Ronald S. Go, MD, David Dingli, MD PhD, Amanda Wilson, PhD, Philippe Gustovic, MD, Aleksandr Kulagin

Blood (2018) 132 (Supplement 1): 1038.

https://doi.org/10.1182/blood-2018-99-111324

Published: 2018

Journal Articles

Interim Analysis of Safety Outcomes during Treatment with Eculizumab: Results from the International Paroxysmal Nocturnal Hemoglobinuria Registry

Anita Hill, MBChB (Hons), PhD, Alexander Roeth, MD, Gérard Socié, MDPhD, Marie-Pierre Caby-Tosi, PharmD, PhD, Amanda Wilson, MPH, PhD, Philippe Gustovic, MD, Camille L. Bedrosian, MD, Robert A. Brodsky, MD

Blood (2017) 130 (Supplement 1): 3486.

https://doi.org/10.1182/blood.V130.Suppl_1.3486.3486

Published: 2017

Journal Articles

Efficacy of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and High Disease Activity with or without History of Aplastic Anemia in the International PNH Registry

Jong-Wook Lee, MD, Regis Peffault De Latour, MD PhD, Robert A. Brodsky, MD, Jun Ho Jang, MD PhD, Anita Hill, MBChB (Hons), PhD, Alexander Roeth, MD, Hubert Schrezenmeier, MD, Amanda Wilson, MPH, PhD, Jing L. Marantz, MD PhD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 3487.

https://doi.org/10.1182/blood.V130.Suppl_1.3487.3487

Published: 2017

Journal Articles

Analysis of Baseline Clinical Characteristics and Disease Burden in Patients Enrolled in the International Paroxysmal Nocturnal Hemoglobinuria Registry

Hubert Schrezenmeier, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Alexander Roeth, MD, David J. Araten, MD, Yuzuru Kanakura, MD PhD, Loree Larratt, MD FRCP(C), Jamile M. Shammo, MD FASCP, FACP, Amanda Wilson, MPH, PhD, Gilda Shayan, Peter Hillmen, MBChB, PhD

Blood (2017) 130 (Supplement 1): 3488.

https://doi.org/10.1182/blood.V130.Suppl_1.3488.3488

Published: 2017

Journal Articles

Comparison of Baseline Clinical Characteristics between Asian Vs. Non-Asian Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) from International PNH Registry

Jun Ho Jang, MD PhD, Shinichiro Okamoto, MD PhD, Masatoshi Sakurai, MD, Wen-Chien Chou, MD, PhD, Jin Seok Kim, MD PhD, Amanda Wilson, MPH, PhD, Jun-Ichi Nishimura, MD PhD, Tzeon-Jye Chiou, MD, Jong-Wook Lee, MD, Yuzuru Kanakura, MD PhD

Blood (2017) 130 (Supplement 1): 3472.

https://doi.org/10.1182/blood.V130.Suppl_1.3472.3472

Published: 2017

Journal Articles

Patients with Paroxysmal Nocturnal Hemoglobinuria and Hemolysis Demonstrate More Frequent Disease-Related Features Than Those without Hemolysis, but Similar Proportions Experience Thromboembolism

Mustafa Nuri Yenerel, MD, Petra Muus, MD PhD, Amanda Wilson, MPH, PhD, Jeff Szer, MB, BS, FRACP

Blood (2015) 126 (23): 3339.

https://doi.org/10.1182/blood.V126.23.3339.3339

Published: 2015

Journal Articles

Different Clinical Characteristics of Paroxysmal Nocturnal Hemoglobinuria in Pediatric and Adult Patients

Alvaro Urbano-Ispizua, Petra Muus, MD PhD, Hubert Schrezenmeier, MD, Antonio Medina Almeida, MD PhD, Amanda Wilson, MPH, PhD, Russell E. Ware, MD PhD

Blood (2015) 126 (23): 3341.

https://doi.org/10.1182/blood.V126.23.3341.3341

Published: 2015

NARROW

Experiences with Efanesoctocog Alfa: Exit Interviews with Caregivers of Previously Treated Patients with Hemophilia A from the XTEND-Kids Phase 3 Clinical Trial

Real-World Unmet Needs in Patients with Hemophilia A without Inhibitors in the US: Results from the PicnicHealth Database

Investigating the Relationship between Endogenous Factor VIII Levels and Annual Bleed Rates and Health-Related Quality of Life in Patients with Hemophilia a Not Treated with Factor VIII Prophylaxis

Experience with Accelerometer Physical Activity Tracking in Adults and Adolescents with Hemophilia A: Tool Validation Using Results from the XTEND-1 Efanesoctocog Alfa Phase 3 Trial

Efficacy of Efanesoctocog Alfa on Pain in Patients with Hemophilia A: Results from the XTEND-1 Phase 3 Clinical Trial in Previously Treated Patients with Hemophilia A

Efficacy of Efanesoctocog Alfa on Physical Functioning: Results from the XTEND-1 Phase 3 Clinical Trial in Previously Treated Patients with Hemophilia A

A Retrospective Observational Descriptive Study on the Effectiveness and Usage of Emicizumab and Antihemophilic Factor (recombinant), Fc Fusion Protein in Patients with Hemophilia A in the US

Treatment Patterns Among Patients with Immune Thrombocytopenia (ITP) in the United States: An Electronic Medical Record (EMR)-Based Analysis

Longitudinal Analysis of Anemia Severity, Treatment and Healthcare Resource Utilization Among Patients with Primary Cold Agglutinin Disease in a Large US Database

Prophylactic Antibiotic Use and Risk of Meningococcal Infections in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Eculizumab Who Received Meningococcal Vaccination: Results from the International PNH Registry

Efficacy of Eculizumab in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria in the International PNH Registry

Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry

Interim Analysis of Safety Outcomes during Treatment with Eculizumab: Results from the International Paroxysmal Nocturnal Hemoglobinuria Registry

Efficacy of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and High Disease Activity with or without History of Aplastic Anemia in the International PNH Registry

Analysis of Baseline Clinical Characteristics and Disease Burden in Patients Enrolled in the International Paroxysmal Nocturnal Hemoglobinuria Registry

Comparison of Baseline Clinical Characteristics between Asian Vs. Non-Asian Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) from International PNH Registry

Patients with Paroxysmal Nocturnal Hemoglobinuria and Hemolysis Demonstrate More Frequent Disease-Related Features Than Those without Hemolysis, but Similar Proportions Experience Thromboembolism

Different Clinical Characteristics of Paroxysmal Nocturnal Hemoglobinuria in Pediatric and Adult Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only